Brief: Vertex Announces US FDA Acceptance Of Biologics License Application For Accelerated Approval Of Povetacicept In IgA Nephropathy
01/06/2026 13:03
BRIEF-Vertex Announces US FDA Acceptance Of Biologics License Application For Accelerated Approval Of Povetacicept In IgA Nephropathy June 1 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O:
VERTEX ANNOUNCES US FDA ACCEPTANCE OF BIOLOGICS LICENSE APPLICATION FOR ACCELERATED APPROVAL OF POVETACICEPT IN IGA NEPHROPATHY
VERTEX PHARMACEUTICALS - FDA SETS PDUFA DATE FOR POVETACICEPT ON NOVEMBER 30, 2026
Source text: ID:nBw4yDmtba
Further company coverage: VRTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vertex Pharmaceuticals
See all newsBrief: Vertex Announces US FDA Acceptance Of Biologics License Application For Accelerated Approval Of Povetacicept In IgA Nephropathy
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings
Vertex Q1 adjusted EPS beats estimates, revenue rises 8%
Vertex tops profit estimates as sales of new cystic fibrosis drug surge
Brief: Vertex Pharmaceuticals Q1 Adjusted EPS USD 4.47 Vs. IBES Estimate USD 4.31